Will the Proteus sensor enhance adherence to aripiprazole or other antipsychotics?

Click to increase image sizeClick to decrease image size

Declaration of interest

P. Masand has acted as a consultant for Allergan, Lundbeck, Merck, Otsuka, Pfizer, Sunovion, Takeda; has received research support from Allergan and Merck; discloses speaker’s bureau from Allergan, Lundbeck, Merck, Otsuka, Pfizer, Sunovion, and Takeda; and discloses stock ownership in Global Medical Education. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Additional information

Funding

This paper was not funded.